TrialBlood2022

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.

Yair Herishanu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.